Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07275021 · ClinicalTrials.gov registry record
Cerebral/ Cortical Visual Impairment: Screening, Identification and Outcome Prediction in Neonates
A clinical trial of Preterm Less Than 32wks With IVH, WMI/PVL and Late Preterm or Term (37-42wks) With Neonatal Encephalopathy Treated With Hypothermia for HIE, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT07275021: Recruiting study of Preterm Less Than 32wks With IVH, WMI/PVL and Late Preterm or Term (37-42wks) With Neonatal Encephalopathy Treated With Hypothermia for HIE, sponsored by Brigham and Women's Hospital.
NCT07275021 is a study of Preterm Less Than 32wks With IVH, WMI/PVL and Late Preterm or Term (37-42wks) With Neonatal Encephalopathy Treated With Hypothermia for HIE that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07275021, a study of Preterm Less Than 32wks With IVH, WMI/PVL and Late Preterm or Term (37-42wks) With Neonatal Encephalopathy Treated With Hypothermia for HIE, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Cerebral/Cortical Visual Impairment (CVI) is the leading cause of childhood visual impairment in the United States and other industrialized countries. CVI is a brain-based visual disorder in which visual acuity or visual fields are reduced despite a normal eye examination or greater-than-expected visual impairment relative to ocular pathology. CVI is increasingly recognized in children with neurological conditions, yet it often remains undiagnosed until later childhood, delaying opportunities for early intervention. Population-based studies suggest that CVI is more common than previously understood. Recent estimates indicate that over 180,000 individuals in the United States aged 0-22 years may have diagnosed or likely CVI, with only a minority formally identified. Children with CVI frequently have co-occurring neurological conditions, including cerebral palsy, epilepsy, developmental delays, or genetic disorders. Infants born preterm or with conditions such as hypoxic-ischemic encephalopathy (HIE), perinatal stroke, or white matter injury are at particularly high risk. Prospective research also shows that a substantial proportion of infants born very preterm exhibit behavioral features of CVI later in childhood. Despite improvements in neonatal neurocritical care, early detection of CVI remains challenging. Current clinical practice focuses on managing conditions such as HIE, perinatal stroke, periventricular leukomalacia, and other brain injuries, but there is limited research evaluating structured early identification pathways for CVI in infancy. Diagnostic tools such as brain MRI and Visual Evoked Potentials (VEP) have shown potential for identifying brain-based visual dysfunction, but their integration into early predictive models for CVI has not been fully explored. This study addresses a critical gap in pediatric care by prospectively evaluating high-risk neonates using clinical, neuroimaging, neurophysiologic, and standardized developmental assessments th
Primary Outcome
Diagnosis of Cerebral/Cortical Visual Impairment (CVI) based on standardized clinical visual assessment performed. Outcome measure: Low, or high risk.
Conditions Studied
Interventions
- OTHER Prospective Clinical and Neurodevelopmental Data Collection
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital, and Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-07-07 |
| Est. Completion | 2028-12-31 |
What NCT07275021 shows while recruiting
NCT07275021 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target.
The record links to 2 conditions, with Preterm Less Than 32wks With IVH, WMI/PVL appearing as the primary indexed condition, and to 1 intervention - of which Prospective Clinical and Neurodevelopmental Data Collection is the first listed.
NCT07275021 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07275021 about?
NCT07275021 is a clinical study titled "Cerebral/ Cortical Visual Impairment: Screening, Identification and Outcome Prediction in Neonates". Cerebral/Cortical Visual Impairment (CVI) is the leading cause of childhood visual impairment in the United States and other industrialized countries. CVI is a brain-based visual disorder in which visual acuity or visual fields are reduced despite a normal eye examination or greater-than-expected vi...
What is the current status of trial NCT07275021?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2025-07-07. Estimated completion is 2028-12-31.
What conditions does trial NCT07275021 study?
This clinical trial studies the following conditions: Preterm Less Than 32wks With IVH, WMI/PVL, Late Preterm or Term (37-42wks) With Neonatal Encephalopathy Treated With Hypothermia for HIE.
What interventions are being tested in trial NCT07275021?
The interventions under investigation include: Prospective Clinical and Neurodevelopmental Data Collection (OTHER).
Who is sponsoring clinical trial NCT07275021?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07275021 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI